ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update
01 août 2024 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
25 avr. 2024 16h15 HE
|
ARCA biopharma, Inc.
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
03 avr. 2024 07h30 HE
|
ARCA biopharma, Inc.
Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company...
ARCA biopharma Announces 2023 Financial Results
01 févr. 2024 16h35 HE
|
ARCA biopharma, Inc.
ARCA biopharma Announces 2023 Financial Results
ARCA biopharma Announces Third Quarter 2023 Financial Results
18 oct. 2023 16h25 HE
|
ARCA biopharma, Inc.
ARCA biopharma Announces Third Quarter 2023 Financial Results
ARCA biopharma Announces Second Quarter 2023 Financial Results
21 juil. 2023 16h25 HE
|
ARCA biopharma, Inc.
Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE...
ARCA biopharma Announces First Quarter 2023 Financial Results
24 avr. 2023 16h25 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update
24 févr. 2023 16h20 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...
James Flynn Joins ARCA biopharma Board of Directors
19 déc. 2022 16h05 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn...
ARCA biopharma Announces Third Quarter 2022 Financial Results
28 oct. 2022 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted...